Loading
companiesCompany
Aosaikang Pharmaceutical
Aosaikang Pharmaceutical is a China-based pharmaceutical company that leads 3 cancer trials in OnCo, testing the anti-CLDN18.2 antibody ASKB589 and the MET inhibitor ASKC202 in non-small-cell lung cancer and advanced solid tumours.
Also called: Jiangsu Aosaikang PharmaceuticalASK Pharm奥赛康药业
Overview
Aosaikang Pharmaceutical is a research-driven pharmaceutical manufacturer listed in Shenzhen that develops, produces and sells active ingredients and finished medicines in gastroenterology, oncology, anti-infectives and chronic disease. Its site cites China's first injectable proton pump inhibitor as a flagship product and lists clinical-stage innovative candidates including molecular glue degraders. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo (2 in phase 3 or 2/3): NCT04632108 (phase 1/2, A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor...), NCT04143607 (phase 3, ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metast...) and NCT07109531 (phase 3, ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Loc...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Nanjing, CN
Scorecard
All companies#59of 1244 companies, score 66
- approved products +24
- targets +2
- modalities +4
- regions +6
- registry trials +30
4 approved, 0 in phase 3, 0 earlier, 1 targets, 8,683 registry studies. Formula on the scorecards page.
Type
Large pharma · SZSE:002755
Stage
Public
Website
Founded
2003
ApprovedOral third-generation EGFR tyrosine kinase inhibitor
Limertinib is Aosaikang's third-generation EGFR inhibitor, approved in China in 2024 for lung cancer with the T790M resistance mutation after earlier EGFR drugs, and in phase 3 trials for first-line use.
ApprovedCytotoxic chemotherapy (platinum)
Carboplatin is a platinum chemotherapy that crosslinks DNA; it is part of the standard pre-surgery regimen for triple-negative breast cancer.
ApprovedCytotoxic chemotherapy (platinum)
Cisplatin · Platinol (generic)
Cisplatin is the original platinum chemotherapy, discovered by accident in 1965; it cures testicular cancer and makes radiation work better in cervical and head and neck cancer.
ApprovedCytotoxic (antifolate)
Pemetrexed · Alimta (and generics)
Pemetrexed is the chemotherapy that, with a platinum drug, became the first approved treatment for mesothelioma in 2004, and is still the backbone today.
Similar pages
- TrialFirmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer.
- TrialA Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell L
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer.
- TrialStudy of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer.
- TrialA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer.
- TrialTusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer.
- TrialA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer.
- TrialStudy of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Can
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer.
cancers
drugs
ApprovedCytotoxic chemotherapy (platinum)
ApprovedCytotoxic chemotherapy (platinum)
Cisplatin · Platinol (generic)
ApprovedOral third-generation EGFR tyrosine kinase inhibitor
ApprovedCytotoxic (antifolate)
Pemetrexed · Alimta (and generics)
trials
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid TumorsASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLCASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy